Samsung Biologics Co Ltd (KO:207940) — Market Cap & Net Worth
Market Cap & Net Worth: Samsung Biologics Co Ltd (207940)
Samsung Biologics Co Ltd (KO:207940) has a market capitalization of $31.37 Billion (₩46.29 Trillion) as of May 4, 2026. Listed on the KO stock exchange, this Korea-based company holds position #842 globally and #16 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Samsung Biologics Co Ltd's stock price ₩1000000.00 by its total outstanding shares 46290951 (46.29 Million). Analyse 207940 cash flow conversion to see how efficiently the company converts income to cash.
Samsung Biologics Co Ltd Market Cap History: 2016 to 2026
Samsung Biologics Co Ltd's market capitalization history from 2016 to 2026. Data shows growth from $4.69 Billion to $31.37 Billion (22.83% CAGR).
Samsung Biologics Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Samsung Biologics Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Samsung Biologics Co Ltd's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.03x
Samsung Biologics Co Ltd's market cap is 0.03 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.69 Billion | $294.62 Billion | -$176.82 Billion | 0.02x | N/A |
| 2017 | $11.52 Billion | $464.63 Billion | -$96.97 Billion | 0.02x | N/A |
| 2018 | $12.00 Billion | $535.81 Billion | $224.11 Billion | 0.02x | 0.05x |
| 2019 | $13.44 Billion | $701.59 Billion | $202.90 Billion | 0.02x | 0.07x |
| 2020 | $25.64 Billion | $1.16 Trillion | $240.97 Billion | 0.02x | 0.11x |
| 2021 | $28.03 Billion | $1.57 Trillion | $393.59 Billion | 0.02x | 0.07x |
| 2022 | $25.76 Billion | $3.00 Trillion | $798.06 Billion | 0.01x | 0.03x |
| 2023 | $23.84 Billion | $3.69 Trillion | $857.69 Billion | 0.01x | 0.03x |
| 2024 | $29.77 Billion | $4.55 Trillion | $1.08 Trillion | 0.01x | 0.03x |
Competitor Companies of 207940 by Market Capitalization
Companies near Samsung Biologics Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Samsung Biologics Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Samsung Biologics Co Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Samsung Biologics Co Ltd's market cap moved from $4.69 Billion to $ 31.37 Billion, with a yearly change of 22.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩31.37 Billion | 0.00% |
| 2025 | ₩31.37 Billion | +5.37% |
| 2024 | ₩29.77 Billion | +24.87% |
| 2023 | ₩23.84 Billion | -7.43% |
| 2022 | ₩25.76 Billion | -8.12% |
| 2021 | ₩28.03 Billion | +9.32% |
| 2020 | ₩25.64 Billion | +90.76% |
| 2019 | ₩13.44 Billion | +12.03% |
| 2018 | ₩12.00 Billion | +4.18% |
| 2017 | ₩11.52 Billion | +145.70% |
| 2016 | ₩4.69 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Samsung Biologics Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $31.37 Billion USD |
| MoneyControl | $31.37 Billion USD |
| MarketWatch | $31.37 Billion USD |
| marketcap.company | $31.37 Billion USD |
| Reuters | $31.37 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Samsung Biologics Co Ltd
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line de… Read more